NetEase, Inc. (NTES) Analysts See $2.41 EPS; Cardionet Has 1.28 Sentiment

January 18, 2018 - By Vivian Park

Analysts expect NetEase, Inc. (NASDAQ:NTES) to report $2.41 EPS on February, 21.They anticipate $1.60 EPS change or 39.90% from last quarter’s $4.01 EPS. NTES’s profit would be $316.33M giving it 33.13 P/E if the $2.41 EPS is correct. After having $2.86 EPS previously, NetEase, Inc.’s analysts see -15.73% EPS growth. The stock decreased 1.56% or $5.055 during the last trading session, reaching $319.345. About 746,132 shares traded. NetEase, Inc. (NASDAQ:NTES) has risen 77.85% since January 18, 2017 and is uptrending. It has outperformed by 61.15% the S&P500.

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The company has market cap of $1.07 billion. The firm operates in three divisions: Healthcare, Research, and Technology. It has a 24.72 P/E ratio. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders.

Among 18 analysts covering NetEase (NASDAQ:NTES), 11 have Buy rating, 4 Sell and 3 Hold. Therefore 61% are positive. NetEase had 40 analyst reports since August 12, 2015 according to SRatingsIntel. The rating was upgraded by Vetr to “Hold” on Wednesday, August 12. The stock has “Buy” rating by Brean Capital on Monday, July 18. Barclays Capital maintained it with “Hold” rating and $320.0 target in Tuesday, November 21 report. The firm has “Buy” rating by CLSA given on Wednesday, January 4. The stock of NetEase, Inc. (NASDAQ:NTES) earned “Hold” rating by Zacks on Tuesday, August 25. On Monday, January 9 the stock rating was upgraded by Standpoint Research to “Buy”. As per Thursday, November 16, the company rating was maintained by Jefferies. The stock has “Sell” rating by CLSA on Thursday, November 16. CLSA upgraded the shares of NTES in report on Monday, October 3 to “Outperform” rating. The stock has “Buy” rating by Goldman Sachs on Wednesday, November 25.

NetEase, Inc. operates an interactive online community in the People's Republic of China. The company has market cap of $41.92 billion. The firm operates through Online Game Services; Advertising Services; and E-mail, E-commerce and Others divisions. It has a 20.76 P/E ratio. It offers PC-client massively multi-player online role-playing games and mobile games; and distributes its point cards to gamers.

Analysts await BioTelemetry, Inc. (NASDAQ:BEAT) to report earnings on February, 28. They expect $0.21 EPS, up 16.67% or $0.03 from last year’s $0.18 per share. BEAT’s profit will be $6.81M for 39.23 P/E if the $0.21 EPS becomes a reality. After $0.16 actual EPS reported by BioTelemetry, Inc. for the previous quarter, Wall Street now forecasts 31.25% EPS growth.

The stock decreased 1.35% or $0.45 during the last trading session, reaching $32.95. About 147,943 shares traded. BioTelemetry, Inc. (BEAT) has risen 87.79% since January 18, 2017 and is uptrending. It has outperformed by 71.09% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: